Sep 8, 2026, 3:43 PM1 views

Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback

Novartis saw a treatment for a rare muscle-wasting disease fail a late-stage study, the third clinical-trial setback in a week. The medicine was the centerpiece of Novartis’s $12 billion.

Bloomberg Verified Source

Syndicated via official news feed

Read Full Story on Bloomberg

Explore all Business stories

Syndicated feed content with full publisher credit.

Business Desk

More in Business

Continue reading verified coverage and related developments on this desk.

View All

BUSINESS9M AGO

I’m a single 58-year-old veteran with $1.5 million in assets and a VA pension. Can I afford to retire?

“I expect to receive at least $9,000 per month before federal and California state taxes.”

BUSINESS9M AGO

Denmark to open new work route in 2027: Eligibility and key rules explained

New plan will cover workers from 16 countries, including India, but applicants must meet salary, job and employer conditions.

BUSINESS9M AGO

Is AfD's historic win in Germany an indication of rise of the far right?

Founded in 2013 as a euro-sceptic party, the AfD has moved sharply right on migration and national identity, turning anger over immigration, economic strain and mainstream politics into votes

BUSINESS9M AGO

Explainer: What is 5G network slicing and why telcos oppose Trai's proposal

5G slicing rules have exposed a split over how network congestion should be measured, with Trai pushing safeguards and operators warning that its 80 per cent PRB threshold could constrain networks

BUSINESS9M AGO

Adani, NTPC among 5 applicants for ₹37,500-cr coal gasification scheme

The Centre's scheme received seven applications from Adani Enterprises, NTPC, Talcher Fertilisers, Gallantt Ispat and Shyam Sel Power for projects in urea, syngas and synthetic gas

BUSINESS9M AGO

Fossil Shark Scales Reveal A 7,000-Year History Of Shark Populations

What if the sharks we see on a reef today are only a fraction of what that ecosystem once supported?